Patient-Reported Continuity of GLP-1 Receptor Agonist Therapy
- Design
- Retrospective cohort · 261 participants · Unknown outcome
- Match to healthy normal-weight adults aged 55–75
- Different population[Auto] Participants had obesity/overweight (age/BMI not reported in abstract).
- Could weight loss explain it?
- Unknown[Auto] Harm signal; weight-loss mediation not the relevant question, but consider whether harms relate to rapid weight loss or reduced intake.
- Study tier
- Study tier 3[Auto] Observational design; confounding by indication and healthy-user effects cannot be excluded (auto-provisional).
- Assessment
- Version 1 · automatic, not yet reviewed by a person · Sep 13, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
[Auto, unreviewed; quoted from abstract conclusions] Patients described obesity-care disruptions primarily as process failures, including prior authorization delay, out-of-pocket cost, pharmacy stock-outs and dispensing delays, and fragmented cross-clinic coordination. They prioritized transparent, workflow-oriented navigation.
01Findings
What the study reported
- Drugs
- Class unspecified
- Primary outcome
- Not extracted
- Effect
- Not extracted
- 95% confidence interval
- Not extracted
- Follow-up
- 6 years
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
- Obesity status
- obesity/overweight present (all or most)
- Sample size
- 261
Study quality details
- Study design
- Retrospective cohort
- Sample size
- 261
- Randomization
- no
- Blinding
- not stated
- Comparator
- not stated
- Follow up duration
- 6 years
- Outcome type
- unknown
- Replication
- not assessed (auto)
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- INDIRECT
- Statistical precision
- not extracted
- Risk of bias
- not assessed (auto)
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- Novo Nordisk, Eli Lilly, Lilly, Boehringer Ingelheim
- Sponsor role
- not reported in abstract
- Author conflicts
- G.S. declares advisory fees from Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Quest Diagnostics, and Madrigal. Y.C., G.P., X.Z., Y.F., C.Y., J.M.S., T.R., D.Y., L.L.N. declare no conflicts of interests relevant to this work.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[OBJECTIVE] Use of GLP-1 receptor agonists is associated with significant weight loss in many individuals. Discontinuation is associated with weight regain. Patients' experience with this is not well characterized. This study describes the patient experience of continuity of care. [METHODS] A cross-sectional electronic survey was administered to adults identified from an academic medical center's electronic health records as having at least one GLP-1 RA prescription in the preceding 6 years and a subsequent prescription gap of greater than 90 days. The 87-item instrument spanned six domains: care settings, comorbidity and treatment context, continuity, discontinuity, dietitian/lifestyle support, and digital-feature preferences. Primary outcomes were item-level frequencies. Exploratory composites included a 7-item Continuity-of-Care Index (CCI) and a 5-item Discontinuity Index (DIS), each rescaled 0-100; subgroup comparisons used Kruskal-Wallis, Mann-Whitney, and chi-square tests, with multiple-imputation sensitivity analyses. [RESULTS] Of 4890 invitations, 261 adults completed the survey (5.3%); 143 (54.8%) reported current use of a prescription weight-management medication and 159 (60.9%) reported prior-authorization requirements. Among them, 79 (49.7%) either waited more than 7 days or were never approved. Continuity strengths included knowing whom to contact about medications (76.2%) and timely team responses (70.7%); the weakest items were cross-clinic coordination (54.1%) and visibility into required next steps (52.2%). The CCI (mean 69.5 [SD 22.7]; α = 0.90; n = 242) varied by most-visited clinic (Kruskal-Wallis p < 0.001), highest at the weight-management clinic (median 82.1) and lower at primary care (60.7). Among current medication users, 32.4% reported a ≥ 14-day medication gap. The most desired digital features were all-in-one tracking of refills, prior authorization, and appointments (89.5%) and real-time prior-authorization status (87.2%). [CONCLUSIONS] Patients described obesity-care disruptions primarily as process failures, including prior authorization delay, out-of-pocket cost, pharmacy stock-outs and dispensing delays, and fragmented cross-clinic coordination. They prioritized transparent, workflow-oriented navigation.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Sep 13, 2026 | 42683049 first ingestion |